New second-line drug for Type 2 diabetes shows promise
London: Type 2 diabetes patients who don`t respond to metformin, the most widely used medication for the disease, may get significant benefit from a new second-line drug, a new study has claimed.
The new drug, linagliptin, results in significantly less weight gain than the most common second-line drugs currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to the study published in The Lancet.
Though metformin is the most commonly prescribed drug to treat diabetes, which affects almost 10 per cent the world`s population, it can become ineffective in the long-term for many patients. Those who do not respond to metformin alone are offered an additional drug known as sulphonylureas.
However, sulphonylureas can lead to hypoglycaemia, or low blood sugar levels, and weight gain, raising the risk of heart attack and stroke.
"Since hypoglycaemia have substantial negative clinical consequences in terms of cognitive function, mortality... And quality of life, its prevention is a crucial component of any diabetes management programme," said study author Prof Baptist Gallwitz of Tubingen University Hospital in Germany.
The new drug, linagliptin - a class of drugs called DPP-4 inhibitors or "gliptins" -- works in a different way by blocking an enzyme known as dipeptidyl peptidase-4 which is involved in glucose metabolism.
This allows the body to increase the amount of insulin it secretes in a glucose-dependent manner, resulting in a very low risk of hypoglycaemia, the researchers said.
Conducted over two years in 16 nations, the study looked at the effects of linagliptin versus glimepiride, one of the most commonly used sulphonylureas, in more than 1,500 patients with Type 2 diabetes who had not achieved normal glucose regulation through the use of metformin alone.
While the two treatments produced comparable improvements in patients` glucose regulation, the study showed side effects of linagliptin were considerably less severe than those with glimepiride, with just seven per cent of patients treated with linagliptin experiencing hypoglycaemia, compared to 38 per cent of patients treated with glimepiride.
The group treated with linagliptin also experienced fewer cardiovascular events such as heart attacks or strokes compared to those treated with glimepiride, the authors said.
However, they stressed that further studies are needed to confirm this, as the study was not long enough to provide reliable evidence that linagliptin results in reduced cardiac risk compared to glimepiride.
More from India
More from World
More from Sports
More from Entertaiment
- Dr Subhash Chandra Show: Aspiring for more than what you have!
- ISIS to buy first nuclear weapon from Pak?
- Mumbai: CCTV captures assailant with gun at Film City
- Mathura SSP receives death threat letter, message for PM Modi
- BJP now central pole of Indian politics: Arun Jaitley
- Reservation issue: Police register case against Bainsla, 20 others
- Watch: Fast N Facts @ 7:30pm
- Zee Media exclusive chat with 'Welcome to Karachi' cast
- Zee Media exclusive interview with Haryana CM Manohar Lal Khattar
- Haridwar: Hotel Radisson Blu sealed for polluting Ganga
- Girl in Punjab's Pathankot quit studies for fear of eve-teasing
- Special: Furious over rising water crisis, people take to the streets
- UP Minister allegedly threatens, abuses Gonda businessman
- Manali: Heavy corruption found in environmental taxes
- Couple in Bihar asked to pay Rs 50,000 as 'tax' for inter-caste marriage
- IPL 2015 Final: MI vs CSK - As it happened...
- IPL 8 Final: We need to be at our best against Mumbai, says Michael Hussey
- Heatwave leaves 153 dead in Telangana, Andhra Pradesh
- Heatwave continues in North India; death toll in Andhra Pradesh, Telangana more than 400
- Heatwave kills 223 in AP, Telangana, Chandrababu Naidu announces compensation; Delhi records hottest day
- CBSE.nic.in 12th XII Results 2015: CBSE Board (cbseresults.nic.in) Class 12th XII Exam Results 2015 to be announced on May 25
- 'Tanu Weds Manu Returns' starts on a good note at the Box Office!
- CBSE 12th Result 2015 to be announced on Monday
- Death threat to PM Narendra Modi ahead of Mathura rally sends police into tizzy
- Organisation demands re-examination of AIPMT 2015
- Standoff with LG: Arvind Kejriwal calls emergency session of Delhi Assembly
- Kejriwal completes 100 days in office, AAP says centre 'shadow boxing' over row with LG
- CBSE Class 12th Board Results 2015 to be announced on Monday, May 25
- Top 5 shopping destinations in Delhi!
- IPL 2015 final: Mumbai Indians thrash Chennai Super Kings by 41 runs to lift second title